Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
Diagnosis and Treatment of Interstitial Lung Disease
share announcement

Diagnosis and Treatment of Interstitial Lung Disease

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2617

Special Issue Editor

Prof. Dr. Roberto G. Carbone

E-Mail Website
Guest Editor
Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy
Interests: respiratory diseases; respiratory pathophysiology; COPD; interstitial lung diseases; pulmonary hypertension; lung transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Interstitial lung disease (ILD) comprises a large group of over 200 parenchymal pulmonary diseases characterized by progressive lung fibrosis. The most common ILDs are non-specific interstitial pneumonia, usual interstitial pneumonia/idiopathic pulmonary fibrosis (UIP/IPF), hypersensitivity pneumonia, and pulmonary sarcoidosis, while rare forms include desquamative interstitial pneumonia, pulmonary Langerhans cell histiocytosis, and lymphangio-leiomyomatosis. Each ILD subtype has distinctive radiographic and pathologic features, with interventional endoscopic procedures such as bronchoscopy, allowing for trans-bronchial biopsies, broncho-alveolar lavage fluid recovery, and cryo-biopsy facilitating accurate diagnoses. Pulmonary arterial hypertension (Group 1) and pulmonary hypertension (Group 3) are frequently detected in patients with ILDs. Treatment includes high steroid doses, antibiotics such as azithromycin, high-flow O2 support, non-invasive ventilation, and, more recently, anti-fibrotic drugs, like pirfenidone and nintedanib. Meanwhile, lung transplantation is the elective treatment for end-stage ILDs.

Current problems include the following: (1) difficulty to control severe exacerbations; (2) analysis of disease progression and outcomes; (3) efficacy of vaso-dilator drugs in pulmonary hypertension; and (4) identification of an accurate composite allocation score.

This Special Issue aims to focus on recent aspects of basic and clinical ILD research.

Suggested topics include the following:

  • UIP/IPF genome analysis;
  • IPF epigenetics;
  • Artificial intelligence in high-resolution computed tomography (HRCT) for ILD diagnosis;
  • Endobronchial ultrasound and cryo-biopsy in ILD;
  • Connective tissue disease-associated ILD;
  • Post-COVID19 ILD;
  • Interstitial lung abnormalities (ILAs).

Prof. Dr. Roberto G. Carbone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interstitial lung disease
  • echocardiography
  • right heart catheterization
  • bronchoscopy
  • HRCT

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

7 pages, 1422 KiB  
Article
Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease
by Tomoyuki Takahashi, Atsushi Saito, Takafumi Yorozuya, Hirotaka Nishikiori, Koji Kuronuma and Hirofumi Chiba
Medicina 2025, 61(5), 892; https://doi.org/10.3390/medicina61050892 - 14 May 2025
Viewed by 498
Abstract
Background: Interstitial lung disease (ILD) is characterized by pulmonary inflammation and fibrosis associated with persistent and refractory cough that significantly hinders quality of life. Conventional treatments for ILD-associated cough have shown limited efficacy, necessitating alternative therapeutic approaches. Gefapixant, a P2X3 receptor antagonist, can [...] Read more.
Background: Interstitial lung disease (ILD) is characterized by pulmonary inflammation and fibrosis associated with persistent and refractory cough that significantly hinders quality of life. Conventional treatments for ILD-associated cough have shown limited efficacy, necessitating alternative therapeutic approaches. Gefapixant, a P2X3 receptor antagonist, can potentially alleviate chronic cough by inhibiting the ATP-mediated activation of sensory C-fibers, but its efficacy in ILD-associated cough remains unclear. This study observed the effects of gefapixant on ILD-associated refractory chronic cough. Methods: This prospective study enrolled patients with ILD-associated refractory chronic cough who received gefapixant at Sapporo Medical University Hospital between July 2022 and November 2023. Cough frequency, Leicester Cough Questionnaire (LCQ) score, cough severity visual analog scale (Cough VAS), and taste VAS were evaluated at baseline and at 2, 4, and 8 weeks after gefapixant administration. Results: Six patients completed the study. Their ILD subtypes included idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and connective tissue disease-associated ILDs (CTD-ILDs). After 8 weeks, the cough frequency decreased from 88.5 to 44.3 episodes per 30 min, LCQ scores increased from 8.3 to 13.6, and cough VAS scores decreased from 75.8 to 40.2. However, statistical significance was not reached due to high interindividual variability, with gefapixant being effective in some and ineffective in others. The most common adverse event was taste disorder, leading to discontinuation in one patient, but symptoms tended to lessen over the course of treatment. Conclusions: Gefapixant appears to be effective in reducing refractory cough related to ILD, although these results were not statistically significant because its effectivity widely varied across individuals. Further investigation is needed to identify patient subgroups with the greatest potential for treatment responsiveness. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Interstitial Lung Disease)
►▼ Show Figures

Figure 1

9 pages, 1883 KiB  
Article
Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by Olcay Aycicek, Serra Keskin, Muhammed Haciosmanoglu, Funda Oztuna, Yilmaz Bulbul and Tevfik Ozlu
Medicina 2025, 61(2), 283; https://doi.org/10.3390/medicina61020283 - 6 Feb 2025
Viewed by 1834
Abstract
Background and Objectives: The aim of our study is to compare the effects of pirfenidone and nintedanib on lung function and radiologic findings in Idiopathic Pulmonary Fibrosis and to identify which drug is more appropriate for which patient group. Materials and Methods: The [...] Read more.
Background and Objectives: The aim of our study is to compare the effects of pirfenidone and nintedanib on lung function and radiologic findings in Idiopathic Pulmonary Fibrosis and to identify which drug is more appropriate for which patient group. Materials and Methods: The data of patients who were treated in our department for at least one year between 1 January 2010 and 31 December 2022 and who were started on pirfenidone or nintedanib treatment with the diagnosis of Idiopathic Pulmonary Fibrosis were retrospectively reviewed. The patients were divided into two groups—the nintedanib and pirfenidone groups—and both groups were compared in terms of progression in lung function tests (changes in FEV1, FVC, 6 MWT and DLCO values at the 3rd, 6th, 9th and 12th months compared to baseline values) and radiological findings (the presence of progression in findings such as ground-glass opacity, reticulation, honeycomb and traction bronchiectasis) within 1 year after diagnosis. Results: The study included 109 patients. The number of patients treated with pirfenidone (IPF patients) was 82 (75.2%) and the number of patients treated with nintedanib was 27 (24.8%). When the PFT values at 3, 6, 9 and 12 months were compared with the baseline values in both groups, there was no statistically significant difference in any parameter between the two groups. No significant difference was found in terms of radiological progression at the end of 1 year in both groups. Conclusions: The results of our study show that pirfenidone and nintedanib are equivalent in their effectiveness in preventing disease progression in patients with IPF. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Interstitial Lung Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop